| Serial Number | 88441516 |
| Word Mark | KYMAB |
| Filing Date | Wednesday, May 22, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, September 7, 2021 |
| Registration Number | 6473731 |
| Registration Date | Tuesday, September 7, 2021 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 23, 2021 |
| Goods and Services | Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, autoimmune and infectious diseases, and medical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodies, for medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases and in the field of antibodies and immuno-oncology |
| Goods and Services | Scientific, medical and technological services, namely, scientific research, analysis and testing in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology, and scientific research, analysis and testing in the field of antibodies and cell repertoires and research, development and design in the field of science, medicine, and technology; industrial analysis and industrial research services, namely, testing, analysis, and evaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, haematology and infectious disease; Conducting clinical trials for others in the field of antibodies, and medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discovery, clinical development, antibodies and biological cells; chemical analysis; chemical research |
| Goods and Services | Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics; Medical screening |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 6, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 6, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 6, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Kymab Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Cambridge CB223AT GB |
| Party Name | Kymab Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Cambridge CB223AT GB |
| Party Name | Kymab Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Cambridge CB223AT GB |
| Event Date | Event Description |
| Tuesday, September 7, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Sunday, August 1, 2021 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Wednesday, April 21, 2021 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, March 23, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 23, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, March 3, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, February 17, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 17, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, February 17, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 17, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 17, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, October 9, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, October 9, 2020 | NON-FINAL ACTION E-MAILED |
| Friday, October 9, 2020 | NON-FINAL ACTION WRITTEN |
| Saturday, August 22, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, August 21, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, August 21, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 16, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, March 16, 2020 | NON-FINAL ACTION E-MAILED |
| Monday, March 16, 2020 | NON-FINAL ACTION WRITTEN |
| Monday, March 9, 2020 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Friday, February 21, 2020 | ELECTRONIC RECORD REVIEW COMPLETE |
| Friday, February 21, 2020 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Friday, February 14, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, February 14, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Friday, February 14, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, February 14, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Friday, February 14, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, January 29, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 28, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 28, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, August 9, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, August 9, 2019 | NON-FINAL ACTION E-MAILED |
| Friday, August 9, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, August 9, 2019 | ASSIGNED TO EXAMINER |
| Thursday, June 6, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, May 25, 2019 | NEW APPLICATION ENTERED IN TRAM |